New Vaccine Blocks Viral Entry in Cattle, May Have Implications for Human Vaccines
April 17, 1997
How could you improve on the immune system? It fights off bacteria and viruses that invade our bodies. How about a new type of vaccine -- one that stops dangerous viruses from even entering the body?
Geoffrey Letchworth, a virologist in the Department of Animal Health and Biomedical Sciences, has developed such an experimental vaccine for bovine herpes virus 1 (BHV-1). When sprayed into a cow's nose, the vaccine stimulates the animal's immune system to make antibodies. These antibodies line the cow's nasal passages and block the virus from entering the animal.
The College of Agricultural and Life Sciences researcher believes the vaccine holds great promise for improving cattle health. BHV-1 infections cause abortions among pregnant cows and lead to shipping fever. These problems cost the U.S. livestock industry hundreds of millions of dollars each year in vaccine and veterinary bills, and in lost production.
Letchworth is equally excited by the implications his findings have for controlling viral diseases in humans. "I think our research here will ultimately benefit human health," he says. "For example, our vaccine is way ahead of vaccines for human herpes viruses." Among the family of human herpes viruses are the viruses that cause cold sores, chicken pox, shingles, roseola, mononucleosis, Kaposi's sarcoma and cytomegalovirus (CMV) infections.
Although there is encouraging new evidence that drugs might eliminate the Human Immunodeficiency Virus from individuals with AIDS, animals and humans do not eliminate herpes viruses once they have become infected. The immune system suppresses these viruses, which hide in the body and can become active again during periods of stress. Current herpes vaccines don't keep out viruses either.
Letchworth's approach builds on scientists' growing understanding of the role mucous membranes play in viral infections.
"When you think about it, most viruses enter animals and people through mucous membranes," Letchworth says. "A few viruses, such as rabies, get into the body other ways. But most cross the mucous membranes around the eyes, or those that line breathing passages, the gastrointestinal tract or reproductive tract."
However, most vaccines are injected into muscle where they are supposed to mimic an actual infection, priming the immune system so it responds quickly when the real virus enters an animal or person.
"When you inject a vaccine into a muscle, the immune system in a lymph node nearby makes antibodies that circulate in the blood and lymph systems," Letchworth says. "But you get a much different response by placing the same antigen on mucosa. That response stimulates a completely different part of the immune system, which appears to protect the body's surfaces. Our idea was to stimulate that part of the immune system."
Letchworth and research assistant Xiaoping Zhu tested the vaccine on 20 cattle from a herpes-free herd. After vaccinating the animals, the scientists challenged each cow with ten million units of BHV-1.
"That's an extraordinarily large dose. That one dose contains enough virus to infect every cow in Wisconsin," Letchworth says. "We wanted the challenge dose to be great enough to infect some animals so we could find the limits of protection. Despite that huge dose, 70 percent of the cows remained free of the virus."
Letchworth also tried the conventional approach in which he injected the vaccine into muscle. When he challenged those cattle with the virus, the vaccine did not protect them. They became infected with BHV-1 and shed it when stressed with steroids.
The UW-Madison virologist doesn't know how long the vaccine will protect cattle. He thinks such a vaccine would be short-lived, probably less than a year. But, he says, animals could be vaccinated over and over fairly easily.
Letchworth has received a U.S. patent on the use of herpes viral glycoproteins for preventing infection. His research has been supported by USDA competitive grants and a Shaw Scholarship.
CONTACT: Geoffrey Letchworth, (608) 262-8616, email@example.com